Alkermes Investigational Site

Washington D.C., District of Columbia 20016

1 studies enrolling now · 12 studies all time

What they study most

Alcohol Use Disorder, Bipolar I Disorder, Major Depressive Disorder, Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Schizophrenia

Studies at this site

• Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects — Enrolling by invitation
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 — Completed
• A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder — Completed
• A Study of ALKS 3831 in Adults With Schizophrenia — Completed
• A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 — Completed
• A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) — Completed
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study — Completed
• A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia — Completed
• A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) — Completed
• An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia — Completed
• A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) — Completed
• An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) — Completed